A practical approach to acromegaly management in Latin America

Pituitary

Volumn 17, Issue SUPPL. 1, 2014, Pages

  Bronstein, Marcello D ^a   Bruno, Oscar D ^b   Abreu, Alin ^c   Mangupli, Ruth ^d   Mercado, Moisés ^e,f  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c CENTRO MÉDICO IMBANACO   (Colombia)

^d HOSPITAL UNIVERSITARIO DE CARACAS   (Venezuela)

^e UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^f HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

Acromegaly; Dopamine agonists; Guidelines; Latin america; Pegvisomant; Somatostatin analogs

Indexed keywords

CABERGOLINE; PEGVISOMANT; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DELAYED DIAGNOSIS; DRUG COST; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH EDUCATION; HUMAN; MEDICAL EXPERT; PATIENT CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOCIAL SUPPORT; SOUTH AND CENTRAL AMERICA; TREATMENT DURATION;

ACROMEGALY; DELAYED DIAGNOSIS; HEALTH SERVICES ACCESSIBILITY; HUMANS; LATIN AMERICA; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SOMATOSTATIN;

EID: 84898829018     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-013-0531-z     Document Type: Article

References (44)

1. de los Monteros ALE, Carrasco CA, Albarrán AAR, Gadelha M, Abreu A, Mercado M (2013) The role of primary pharmacological therapy in acromegaly. Pituitary. doi:10.1007/s11102-013-0530-0
2. Vilar L, Valenzuela A, Ribeiro-Oliveira A Jr, Gómez Giraldo CM, Pantoja D, Bronstein MD (2013) Multiple facets in the control of acromegaly. Pituitary. doi:10.1007/s11102-013-0536-7
3. Guitelman M, Abreu A, Espinosa-de-los-Monteros AL, Mercado M (2013) Patient-focussed outcomes in acromegaly. Pituitary. doi:10.1007/s11102-013-0519- 8
4. Carrasco CA, Gadelha M, Manavela M, Bruno OD (2013) Aggressive tumors and difficult choices in acromegaly. Pituitary. doi:10.1007/s11102-013-0538-5
5. Barreto SM, Miranda JJ, Figueroa JP, Schmidt MI, Munoz S, Kuri-Morales PP, Silva JB Jr (2012) Epidemiology in Latin America and the Caribbean: current situation and challenges. Int J Epidemiol 41(2):557-571
6. Pichon-Riviere A, Augustovski F, García Martí S, Sullivan SD, Drummond M (2012) Transferability of health technology assessment reports in Latin America: an exploratory survey of researchers and decision makers. Int J Technol Assess Health Care 28(2):180-186
7. Pichon-Riviere A, Augustovski F, Rubinstein A, Martí SG, Sullivan SD, Drummond MF (2010) Health technology assessment for resource allocation decisions: are key principles relevant for Latin America? Int J Technol Assess Health Care 26(4):421-427
8. Acevedo K, Aguilar-Pacheco PE, Arellano Montaño S, Bastidas-Adrián MY, Domínguez B, García AR, Gómez-Martínez G, González-Estrada J, Hernández A, Hidalgo L, Jervis P, Luna-Ceballos RI, Maya-Luna M, Mercado M, Vidrio M, Padilla-Retana JA, Portocarrero L, Rangel-Sánchez G, Reza-Albarrán A, Rivera A, Trujillo-Lozoya C, Uribe AM, Velázquez FJ, Vergara A (2010) Primer reporte del registro nacional de acromegalia: Programa "Epiacro". Revista de Endocrinología y Nutrición 18(4):176-180
9. Jervis P, Trujillo C, Portocarrero L, Domínguez B, Vidrio M, Luna-Ceballos RI, Reza A, Velázquez F, Maya-Luna ML, Gómez G, Acevedo K, García R, Mercado M(2012) "Epiacro": The Mexican Acromegaly Registry [Abstract]. Endocr Rev 33(03-MeetingAbstracts): MON-717
10. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85(2):526-529 (Pubitemid 32273628)
11. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A (2002) Guidelines for acromegaly management. J Clin Endocrinol Metab 87: 4054-4058
12. Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S (2003) Pituitary society and the European neuroendocrine Association. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 26(12): 1242-1247
13. Giustina A, Barkan A, Chanson P, Grossman A, Hoffman A, Ghigo E, Casanueva F, Colao A, Lamberts S, Sheppard M, Melmed S (2008) Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 31(9):820-838
14. Acromegaly Consensus Group, Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5):1509-1517
15. Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JA, Giustina A (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16(3):294-302
16. Barkan A, Bronstein MD, Bruno OD, Cob A, Espinosa-de-los-Monteros AL, Gadelha MR, Garavito G, Guitelman M, Mangupli R, Mercado M, Portocarrero L, Sheppard M (2010) Management of acromegaly in Latin America: expert panel recommendations. Pituitary 13(2):168-175
17. Arellano S, Aguilar P, Domínguez B, de Los E, Monteros AL, González Virla B, Sosa E, Mercado M, Guinto G, Martínez I, Hernández E, Reza A, Portocarrero L, Vergara A, Velázquez FJ, Ramírez E (2007) Segundo Consenso Nacional de Acromegalia: recomendaciones para su diagnóstico, tratamiento y seguimiento. Revista de Endocrinología y Nutrición 15(3 Suppl 1):S7-S16
18. Vieira Neto L, Abucham J, Araujo LA, Boguszewski CL, Bronstein MD, Czepielewski M, Jallad RS, Musolino NR, Naves LA, Ribeiro-Oliveira Júnior A, Vilar L, Faria Mdos S, Gadelha MR (2011) Recommendations of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil. Arq Bras Endocrinol Metabol 55(2):91-105
19. Mangupli R, Lisette A, Ivett C, Paul C, de los Ríos Victoria C, Luis CJ (2003) Improvement of acromegaly after octreotide LAR treatment. Pituitary 6(1):29-34 (Pubitemid 37455642)
20. Jallad RS, Musolino NR, Salgado LR, Bronstein MD (2005) Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol 63(2):168-175 (Pubitemid 41097985)
21. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J; SMS995B2401 Study Group (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol 66(6):859-868 (Pubitemid 47024274)
22. Murray RD, Melmed S (2008) A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 93(8):2957-2968
23. Sosa E, Espinosa-de-los-Monteros AL, González B, Vargas G, Mier F, Mercado M (2008) Treatment of acromegaly with octreotide LAR. Rev Med Inst Mex Seguro Soc 46(6):651-658
24. Bronstein MD (2010) Optimizing acromegaly treatment. Front Horm Res 38:174-183
25. Jallad RS, Bronstein MD (2009) Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology 90(1):82-92
26. Mattar P, Alves Martins MR, Abucham J (2010) Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling IGF-I levels in acromegaly. Neuroendocrinology 92(2):120-127
27. Vilar L, Azevedo MF, Naves LA, Casulari LA, Albuquerque JL, Montenegro RM, Montenegro RM Jr, Figueiredo P, Nascimento GC, Faria MS (2011) Role of the addition of cabergoline to the management of acromegalic patients resistant to long-term treatment with octreotide LAR. Pituitary 14(2):148-156
28. Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ (2009) Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 160(4):529-533
29. van der Lely AJ, Bernabeu I, Cap J, Caron P, Colao A, Marek J, Neggers S, Birman P (2011) Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol 164(3):325-333
30. Shimon I, Barkan A (2012) Estrogen treatment for acromegaly. Pituitary 15(4):601-607
31. Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD (2007) Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol 67(2):310-315 (Pubitemid 47076313)
32. Mao ZG, Zhu YH, Tang HL, Wang DY, Zhou J, He DS, Lan H, Luo BN, Wang HJ (2010) Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol 162(4):661-666
33. Abrams P, Alexopoulou O, Abs R, Maiter D, Verhelst J (2007) Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. Eur J Endocrinol 157(5):571-577 (Pubitemid 350187373)
34. Ramírez C, Vargas G, González B, Grossman A, Rábago J, Sosa E, Espinosa-de-Los-Monteros AL, Mercado M (2012) Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying? Eur J Endocrinol 166(1):21-26
35. Jallad RS, Musolino NR, Salgado LR, Bronstein MD (2007) Treatment of acromegaly: is there still a place for radiotherapy? Pituitary 10(1):53-59 (Pubitemid 46562808)
36. González B, Vargas G, Espinosa-de-los-Monteros AL, Sosa E, Mercado M (2011) Efficacy and safety of radiotherapy in acromegaly. Arch Med Res 42(1):48-52
37. Minniti G, Scaringi C, Amelio D, Maurizi Enrici R (2012) Stereotactic irradiation of GH-secreting pituitary adenomas. Int J Endocrinol 2012:482861
38. Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU (2010) Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol 72(2):203-208
39. Psaras T, Milian M, Hattermann V, Freiman T, Gallwitz B, Honegger J (2011) Demographic factors and the presence of comorbidities do not promote early detection of Cushing's disease and acromegaly. Exp Clin Endocrinol Diabetes 119(1):21-25
40. Knutzen R, Ezzat S (2006) The cost of medical care for the acromegalic patient. Neuroendocrinology 83(3-4):139-144 (Pubitemid 44578865)
41. Rosario PW, Calsolari MR (2012) Screening for acromegaly by application of a simple questionnaire evaluating the enlargement of extremities in adult patients seen at primary health care units. Pituitary 15(2):179-183
42. Kasuki L, Marques NV, Nuez MJ, Leal VL, Chinen RN, Gadelha MR (2013) Acromegalic patients lost to follow-up: a pilot study. Pituitary 16(2):245-250
43. Espinosa-de-los-Monteros AL, Sosa E, Cheng S, Ochoa R, Sandoval C, Guinto G, Mendoza V, Hernández I, Molina M, Mercado M (2006) Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status. Clin Endocrinol 64(3):245-249
44. McLaughlin N, Laws ER, Oyesiku NM, Katznelson L, Kelly DF (2012) Pituitary centers of excellence. Neurosurgery 71(5):916-924